Core Viewpoint - The article reports that BeiGene (300558.SZ) has received a drug registration certificate from the National Medical Products Administration (NMPA) for the launch of its biosimilar drug, Perjeta (pertuzumab injection), in collaboration with Hangzhou Bozhrui Biopharmaceutical Co., Ltd. [1] Group 1 - The NMPA has approved the market launch of the biosimilar pertuzumab injection, branded as Bezetin® [1] - Bezetin® is developed by Bozhrui Biopharmaceutical, a wholly-owned subsidiary of Zhejiang Bozhrui Biopharmaceutical Co., Ltd. [1] - The drug is indicated for the treatment of early-stage breast cancer and metastatic breast cancer [1]

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for its collaboration with Hangzhou Bozhi Rui Biopharmaceutical Co., Ltd. to market the biosimilar drug Pertuzumab injection (brand name: Bezetin®) for early and metastatic breast cancer patients [1] Group 1 - The drug Bezetin® is a biosimilar of Pertuzumab, independently developed by Bozhi Rui Biopharmaceutical [1] - The approval allows the company to advance the commercialization efforts for Bezetin® [1] - Bezetin® is indicated for the treatment of early breast cancer and metastatic breast cancer [1]